Evaluation of the association of urokinase plasminogen activator system gene polymorphisms with susceptibility and pathological development of hepatocellular carcinoma

Annals of Surgical Oncology

Volumn 17, Issue 12, 2010, Pages 3394-3401

  Weng, Chia Jui ^a   Tsai, Chiung Man ^b   Chen, Yi Chen ^c   Hsieh, Yi Hsien ^d   Lin, Chiao Wen ^d   Liu, Yu Fan ^d   Su, Shih Chi ^e   Chen, Mu Kuan ^d,f,g   Yang, Shun Fa ^d,h  

^a TAINAN UNIVERSITY OF TECHNOLOGY   (Taiwan)

^b Chest Hospital   (Taiwan)

^c NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^d CHUNG SHAN MEDICAL UNIVERSITY   (Taiwan)

^e TEXAS A AND M UNIVERSITY SYSTEM   (United States)

^f CHANGHUA CHRISTIAN HOSPITAL   (Taiwan)

^g MINGDAO UNIVERSITY   (Taiwan)

^h CHUNG SHAN MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARTATE AMINOTRANSFERASE; HEPATITIS B SURFACE ANTIGEN; PROUROKINASE; UROKINASE; UROKINASE RECEPTOR;

ADULT; AGED; ARTICLE; CARCINOGENESIS; CLINICAL ASSESSMENT; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE ASSOCIATION; DNA POLYMORPHISM; FEMALE; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENOTYPE; HUMAN; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PREDICTIVE VALUE; PROGNOSIS; RESTRICTION FRAGMENT LENGTH POLYMORPHISM;

AGED; CARCINOMA, HEPATOCELLULAR; CASE-CONTROL STUDIES; DISEASE PROGRESSION; DNA, NEOPLASM; FEMALE; GENOTYPE; HUMANS; LIVER; LIVER NEOPLASMS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM STAGING; PLASMINOGEN ACTIVATOR INHIBITOR 1; POLYMERASE CHAIN REACTION; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; RECEPTORS, UROKINASE PLASMINOGEN ACTIVATOR; UROKINASE-TYPE PLASMINOGEN ACTIVATOR;

EID: 78650980625     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-010-1124-y     Document Type: Article

References (37)

1. DH Berger 2002 Plasmin/plasminogen system in colorectal cancer World J Surg 26 767 771 10.1007/s00268-002-4050-8 11965442 (Pubitemid 36920315)
2. F Blasi P Carmeliet 2002 uPAR: a versatile signalling orchestrator Nat Rev Mol Cell Biol 3 932 943 1:CAS:528:DC%2BD38XptFKnt7c%3D 10.1038/nrm977 12461559 (Pubitemid 35477371)
3. N Sidenius F Blasi 2003 The urokinase plasminogen activator system in cancer: recent advances and implication for prognosis and therapy Cancer Metastasis Rev 22 205 222 1:CAS:528:DC%2BD3sXis1CjtL8%3D 10.1023/A:1023099415940 12784997 (Pubitemid 36561058)
4. PA Andreasen L Kjoller L Christensen MJ Duffy 1997 The urokinase-type plasminogen activator system in cancer metastasis: a review Int J Cancer 72 1 22 1:CAS:528:DyaK2sXkslahsbk%3D 10.1002/(SICI)1097-0215(19970703)72:1<1::AID- IJC1>3.0.CO;2-Z 9212216 (Pubitemid 27314632)
5. K Danø J Rømer BS Nielsen S Bjørn C Pyke J Rygaard LR Lund 1999 Cancer invasion and tissue remodeling-cooperation of protease systems and cell types APMIS 107 120 127 10.1111/j.1699-0463.1999.tb01534.x 10190288
6. MJ Duffy TM Maguire EW McDermott N O'Higgins 1999 Urokinase plasminogen activator: a prognostic marker in multiple types of cancer J Surg Oncol 71 130 135 1:CAS:528:DyaK1MXktlShu7k%3D 10.1002/(SICI)1096-9098(199906)71:2<130:: AID-JSO14>3.0.CO;2-9 10389872 (Pubitemid 29288493)
7. K Dass A Ahmad AS Azmi SH Sarkar FH Sarkar 2008 Evolving role of uPA/uPAR system in human cancers Cancer Treat Rev 34 122 136 1:CAS:528: DC%2BD1cXjtl2jsb0%3D 10.1016/j.ctrv.2007.10.005 18162327
8. T Sakakibara K Hibi M Koike, et al. 2005 Plasminogen activator inhibitor-1 as a potential marker for the malignancy of colorectal cancer Br J Cancer 93 799 803 1:CAS:528:DC%2BD2MXhtVeksbvJ 10.1038/sj.bjc.6602743 16091756 (Pubitemid 41486440)
9. B Han M Nakamura I Mori Y Nakamura K Kakudo 2005 Urokinase-type plasminogen activator system and breast cancer (Review) Oncol Rep 14 105 112 1:CAS:528:DC%2BD2MXmt1ChtbY%3D 15944776
10. C Duggan S Kennedy MD Kramer C Barnes P Elvin E McDermott, et al. 1997 Plasminogen activator inhibitor type 2 in breast cancer Br J Cancer 76 622 627 1:STN:280:DyaK2svkslKhsw%3D%3D 9303361
11. M Fredstorp-Lidebring PO Bendahl N Brunner B Casslen T Hogberg E Langstrom-Einarsson, et al. 2001 Urokinase plasminogen activator and its inhibitor PAI-1, in association with progression-free survival in early stage endometrial cancer Eur J Cancer 37 2339 2348 1:CAS:528:DC%2BD3MXosFKgtLg%3D 10.1016/S0959-8049(01)00306-9 11720826 (Pubitemid 33097469)
12. J Abe T Urano H Konno Y Erhan T Tanaka N Nishino, et al. 1999 Larger and more invasive colorectal carcinoma contains larger amounts of plasminogen activator inhibitor type 1 and its relative ratio over urokinase receptor correlates well with tumour size Cancer 86 2602 2611 1:CAS:528: DC%2BD3cXlsVKitA%3D%3D 10.1002/(SICI)1097-0142(19991215)86:12<2602::AID- CNCR4>3.0.CO;2-S 10594855 (Pubitemid 30004664)
13. F Janicke A Prechtl C Thomssen N Harbeck C Meisner M Untch, et al. 2001 Randomized adjuvant chemotherapy trial in highrisk, lymph node-negative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 J Natl Cancer Inst 93 913 920 1:CAS:528:DC%2BD3MXltV2ltLc%3D 10.1093/jnci/93.12.913 11416112
14. KW Klinger R Winqvist A Riccio PA Andreasen R Sartorio LS Nielsen, et al. 1987 Plasminogen activator inhibitor type 1 gene is located at region q21.3-q22 of chromosome 7 and genetically linked with cystic fibrosis Proc Natl Acad Sci U S A 84 8548 8552 1:CAS:528:DyaL1cXmvF2ksg%3D%3D 10.1073/pnas.84.23.8548 2891140
15. PJ Bosma EA van den Berg T Kooistra DR Siemieniak JL Slightom 1988 Human plasminogen activator inhibitor-1 gene J Biol Chem 263 9129 9141 1:CAS:528:DyaL1MXjsVGrtQ%3D%3D 3132455
16. SJ Dawson B Wiman A Hamsten F Green S Humphries AM Henney 1993 The two allele sequences of a common polymorphism in the promoter of the plasminogen activator inhibitor-1 (PAI-1) gene respond differently to IL-1 in Hep G2 cells J Biol Chem 268 10739 10745 1:CAS:528:DyaK3sXkt1Kntr4%3D 8388372
17. P Eriksson B Kallin FM van 't Hooft, et al. 1995 Allele-specific increase in basal transcription of the plasminogen-activator inhibitor 1 gene is associated with myocardial infarction Proc Natl Acad Sci U S A 92 1851 1855 1:CAS:528:DyaK2MXksVCru7g%3D 10.1073/pnas.92.6.1851 7892190
18. FX Bosch J Ribes R Cleries M Diaz 2005 Epidemiology of hepatocellular carcinoma Clin Liver Dis 9 191 211 10.1016/j.cld.2004.12.009 15831268
19. Department of Health, Republic of China. Health statistics: II. Vital statistics. Taipei: Department of Health; 2007.
20. PA Farazi RA DePinho 2006 Hepatocellular carcinoma pathogenesis: from genes to environment Nat Rev Cancer 6 674 687 1:CAS:528:DC%2BD28XosVOmsLs%3D 10.1038/nrc1934 16929323 (Pubitemid 44286000)
21. Firpi RJ, Nelson DR. Viral hepatitis: manifestations and management strategy. Hematol Am Soc Hematol Educ Program. 2006;375-80.
22. Y Yano F Yamashita K Kuwaki K Fukumori O Kato H Yamamoto, et al. 2006 Clinical features of hepatitis C virusrelated hepatocellular carcinoma and their association with alpha-fetoprotein and protein induced by vitamin K absence or antagonist-II Liver Int 26 789 795 1:CAS:528:DC%2BD28XhtVegsrvL 10.1111/j.1478-3231.2006.01310.x 16911460 (Pubitemid 44165246)
23. CC Chang SC Chen YH Hsieh YC Chen TY Chen YH Chu, et al. 2009 Stromal cell-derived factor-1 but not its receptor, CXCR4, gene variants increase susceptibility and pathological development of hepatocellular carcinoma Clin Chem Lab Med 47 412 418 1:CAS:528:DC%2BD1MXlvVGgsLk%3D 10.1515/CCLM.2009.092 19327121
24. H AkkIz S Bayram A Bekar B Ozdil E Akgöllü AT Sümbül, et al. 2009 G-308A TNF-alpha polymorphism is associated with an increased risk of hepatocellular carcinoma in the Turkish population: Case-control study Cancer Epidemiol 33 261 264 10.1016/j.canep.2009.06.001 19683483
25. CJ Weng YH Hsieh CM Tsai YH Chu KC Ueng YF Liu, et al. 2010 Relationship of insulin-like growth factors system gene polymorphisms with the susceptibility and pathological development of hepatocellular carcinoma Ann Surg Oncol 17 1808 1815 10.1245/s10434-009-0904-8 20119675
26. MC Tsai KM Kee YD Chen LC Lin LS Tsai HH Chen, et al. 2007 Excess mortality of hepatocellular carcinoma and morbidity of liver cirrhosis and hepatitis in HCV-endemic areas in an HBV-endemic country: geographic variations among 502 villages in southern Taiwan J Gastroenterol Hepatol 22 92 98 10.1111/j.1440-1746.2006.04489.x 17201888 (Pubitemid 44953423)
27. TH Chen CJ Chen MF Yen SN Lu CA Sun GT Huang, et al. 2002 Ultrasound screening and risk factors for death from hepatocellular carcinoma in a high risk group in Taiwan Int J Cancer 98 257 261 1:CAS:528:DC%2BD38XhsVSkuro%3D 10.1002/ijc.10122 11857416 (Pubitemid 34150810)
28. CJ Chen MW Yu YF Liaw 1997 Epidemiological characteristics and risk factors of hepatocellular carcinoma J Gastroenterol Hepatol 12 S294 S308 1:STN:280:DyaK1c%2FntFansw%3D%3D 10.1111/j.1440-1746.1997.tb00513.x 9407350
29. Y Wang 2001 The role and regulation of urokinase-type plasminogen activator receptor gene expression in cancer invasion and metastasis Med Res Rev 21 146 170 10.1002/1098-1128(200103)21:2<146::AID-MED1004>3.0.CO;2-B 11223863 (Pubitemid 32185245)
30. V Pillay CR Dass PF Choong 2007 The urokinase plasminogen activator receptor as a gene therapy target for cancer Trends Biotechnol 25 33 39 1:CAS:528:DC%2BD2sXhsFWguw%3D%3D 10.1016/j.tibtech.2006.10.011 17084931 (Pubitemid 46001467)
31. R Castelló F Espana C Vazquez, et al. 2006 Plasminogen activator inhibitor-1 4G/5G polymorphism in breast cancer patients and its association with tissue PAI-1 levels and tumor severity Thromb Res 117 487 492 10.1016/j.thromres.2005.03.025 15907980 (Pubitemid 43326132)
32. F Janicke M Schmitt H Graeff 1991 Clinical relevance of the urokinase-type and tissue-type plasminogen activators and of their type 1 inhibitor in breast cancer Semin Thromb Hemost 17 303 312 1:STN:280: DyaK387nvFOgtg%3D%3D 10.1055/s-2007-1002624 1796300
33. HJ Nielsen H Pappot IJ Christensen, et al. 1998 Association between plasma concentrations of plasminogen activator inhibitor-1 and survival in patients with colorectal cancer Br Med J 316 829 830 1:STN:280: DyaK1c3htVKhsw%3D%3D
34. K Bajou C Maillard M Jost, et al. 2004 Host-derived plasminogen activator inhibitor-1 (PAI-1) concentration is critical for in vivo tumoral angiogenesis and growth Oncogene 23 6986 6990 1:CAS:528:DC%2BD2cXnsFaitrc%3D 10.1038/sj.onc.1207859 15286708 (Pubitemid 39279999)
35. JJ Alvarez-Millán C Bocos V Ferrín AR Lucas A Ruibal J Schneider 2002 PAI-1 promoter polymorphism modulates uPA-PAI complex accumulation by breast cancer cells Oncology 62 286 290 10.1159/000059577 12065877 (Pubitemid 34639063)
36. B Smolarz J Blasiak A Kulig, et al. 2001 Plasminogen activator inhibitor 1 (PAI-1) levels and gene promoter polymorphisms in subjects with colorectal cancer J Exp Clin Cancer Res 20 247 252 1:CAS:528:DC%2BD3MXlslGrsLg%3D 11484982
37. H Lei K Hemminki R Johansson A Altieri K Enquist R Henriksson P Lenner A Försti 2008 PAI-1-675 4G/5G polymorphism as a prognostic biomarker in breast cancer Breast Cancer Res Treat 109 165 175 1:CAS:528:DC%2BD1cXkslKhsrk%3D 10.1007/s10549-007-9635-3 17616807 (Pubitemid 351538765)